Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

International Scientists' Network To Map Drug-Resistant Malaria
PTI/Hindu reports on the Worldwide Antimalarial Resistance Network (WWARN) - an "international network of malaria scientists," which will be "established to map the emergence of resistance" to malaria drugs and "guide global efforts to control and eradicate the disease." The goal of WWARN, which "will integrate the efforts of researchers, NGOs and public health experts in malaria-endemic areas around the world," is to provide "comprehensive and rigorous evidence" for policy makers, which will help them "select the best anti-malarial treatments and to formulate strategies to control the critical problem of resistance wherever it arises," PTI/Hindu writes.

New Nice Guideline For Type 2 Diabetes Recognises Benefits From Newer Agents For Blood Glucose Control
Merck Sharp & Dohme Limited (MSD) welcomes the publication of the guideline for type 2 diabetes newer agents1 from the National Institute for Health and Clinical Excellence (NICE) in the UK, which recommends considering a range of newer therapy options, including "Januvia" (sitagliptin). The guideline recommends that the DPP-4 inhibitor class, which includes sitagliptin, should be considered as a second line therapy instead of a sulphonylurea (SU) when blood glucose control remains or becomes inadequate (HbA1c ð‰¥ 6.5% or other higher level agreed with the individual) with metformin in patients at significant risk of hypoglycaemia or its consequences, or if a patient does not tolerate an SU or an SU is contraindicated.1
News of the day
Sanofi-Aventis, GlaxoSmithKline Will Donate Influenza Vaccines To WHO
The drugmaker Sanofi-Aventis will donate millions of doses of a vaccine that offers protection against the H1N1 (swine flu) virus to the WHO once the vaccine is ready, the company"s chief executive officer announced Tuesday, Reuters reports (Elsner, Reuters, 6/17). The AP/Google.com writes, "Exceptional times require exceptional responses. We need to act responsibly and we all have to play our part," Sanofi CEO Christopher Viehbacher said in a statement released during the Pacific Health Summit in Seattle. "This flexible donation aims to help the WHO address the needs of these most vulnerable populations," he said.
Public Health

Gene Network Sciences Announces Broad Cancer Collaboration With UCSF And Initial Results

Gene Network Sciences, Inc. (GNS) announced that it has entered into a research collaboration with the University of California San Francisco Cancer Center (UCSF) aimed at accelerating cancer research and drug development across several therapeutic areas. This collaboration will combine the clinical and research oncology expertise of UCSF with the computational expertise and supercomputer-driven REFS(TM) platform of GNS. Financial terms of the agreement were not disclosed. GNS and UCSF have utilized REFS(TM) to discover and validate novel mediators of the cell cycle transition, which is a critical determinant of the rate of cancer cell proliferation and tumor growth. These results were presented by UCSF researcher Dr. Rina Gendelman, a post-doctoral fellow in Dr. W. Michael Korn"s laboratory, at the American Association for Cancer Research 2009 meeting on April 18-22 in Denver, during which Dr. Gendelman received an AACR-Susan G. Komen Scholar-in-Training Award. GNS and prominent UCSF investigators Dr. Joe Gray, Dr. Frank McCormick, and Dr. W. Michael Korn will continue the collaboration through a number of additional projects. Dr. Korn, who is an Associate Professor at UCSF, will lead the UCSF-GNS research partnership. The parties will continue with research to elucidate the RAS-MAPK and PI3K cancer pathways, pathways critical for initiation and progression of many cancers, by building models of breast, pancreatic, and esophageal cancer based on data from ongoing research at UCSF using the REFS(TM) platform and simulation of these models. The discoveries from the ongoing research are expected to include potential novel drug targets in those cancer types. "GNS is excited to be working with UCSF, a world-class research and clinical institution, to tackle key current issues in cancer research," said Dr. Iya Khalil, Executive Vice President and co-founder of GNS. "Our collaborative work with UCSF is one of several examples of GNS"s applying our supercomputer-driven REFS(TM) platform to accelerate better treatments for patients with cancer." Gene Network Sciences and The University of California


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009